SREBF1 and metabolic dysfunction-associated steatohepatitis: Furthermore, anti-progressive effect was clear by decreasing de-novo lipogenesis cascade by suppressing SREBP-1c and FAS, as de-novo lipogenesis is one major NASH hallmark that is one of the major causes of hepatic steatosis.